ES2650167T3 - Relaciones farmacológicas fijas para el tratamiento de cánceres hematopoyéticos y trastornos proliferativos - Google Patents

Relaciones farmacológicas fijas para el tratamiento de cánceres hematopoyéticos y trastornos proliferativos Download PDF

Info

Publication number
ES2650167T3
ES2650167T3 ES08730048.9T ES08730048T ES2650167T3 ES 2650167 T3 ES2650167 T3 ES 2650167T3 ES 08730048 T ES08730048 T ES 08730048T ES 2650167 T3 ES2650167 T3 ES 2650167T3
Authority
ES
Spain
Prior art keywords
cytarabine
daunorubicin
aml
unanswered
fixed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08730048.9T
Other languages
English (en)
Spanish (es)
Inventor
Arthur Louie
Christine Swenson
Lawrence Mayer
Andrew Janoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Therapeutics Inc
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39690832&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2650167(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2650167T3 publication Critical patent/ES2650167T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
ES08730048.9T 2007-02-16 2008-02-15 Relaciones farmacológicas fijas para el tratamiento de cánceres hematopoyéticos y trastornos proliferativos Active ES2650167T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US90177207P 2007-02-16 2007-02-16
US901772P 2007-02-16
US96519607P 2007-08-17 2007-08-17
US965196P 2007-08-17
PCT/US2008/054168 WO2008101214A2 (en) 2007-02-16 2008-02-15 Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Publications (1)

Publication Number Publication Date
ES2650167T3 true ES2650167T3 (es) 2018-01-17

Family

ID=39690832

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08730048.9T Active ES2650167T3 (es) 2007-02-16 2008-02-15 Relaciones farmacológicas fijas para el tratamiento de cánceres hematopoyéticos y trastornos proliferativos
ES17200498T Active ES2909903T3 (es) 2007-02-16 2008-02-15 Proporciones fijas de medicamentos para el tratamiento de cáncer hematopoyético y trastornos proliferativos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17200498T Active ES2909903T3 (es) 2007-02-16 2008-02-15 Proporciones fijas de medicamentos para el tratamiento de cáncer hematopoyético y trastornos proliferativos

Country Status (20)

Country Link
US (2) US8092828B2 (enExample)
EP (3) EP4046640A1 (enExample)
JP (1) JP5314600B2 (enExample)
KR (2) KR20100014441A (enExample)
CN (1) CN105998046A (enExample)
AU (1) AU2008216083B2 (enExample)
CA (1) CA2678332C (enExample)
CY (1) CY1119631T1 (enExample)
DK (2) DK3300601T3 (enExample)
ES (2) ES2650167T3 (enExample)
FR (1) FR22C1034I2 (enExample)
HR (1) HRP20220428T3 (enExample)
HU (2) HUE058334T2 (enExample)
LU (1) LUC00271I2 (enExample)
NL (1) NL301185I2 (enExample)
NO (2) NO2120568T3 (enExample)
PL (2) PL2120568T3 (enExample)
PT (2) PT3300601T (enExample)
SI (1) SI3300601T1 (enExample)
WO (1) WO2008101214A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010036822A1 (en) * 2008-09-24 2010-04-01 Hollis-Eden Pharmaceuticals, Inc. Patient populations and treatment methods
CA2852777C (en) * 2011-10-21 2020-10-27 Celator Pharmaceuticals Inc. Lyophilized liposomes
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
WO2015127173A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015127172A1 (en) * 2014-02-20 2015-08-27 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US10927418B2 (en) 2015-11-11 2021-02-23 Celator Pharmaceuticals, Inc. Assays and methods for selecting a treatment regimen for a subject with leukemia
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019023873A1 (zh) * 2017-07-31 2019-02-07 江苏竞诺择生物医药科技有限公司 一种用于治疗造血系统增殖性疾病的纳米脂质微粒组合物及药用组合物
JP2022502498A (ja) * 2018-09-25 2022-01-11 セレーター ファーマシューティカルズ インコーポレイテッド 血液疾患の低強度治療
US12029792B2 (en) 2018-12-04 2024-07-09 Der-Yang Tien Stereocomplexes for the delivery of anti-cancer agents
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
CN1720044A (zh) * 2002-11-06 2006-01-11 惠氏公司 急性白血病和骨髓异常增生综合征的组合治疗
AU2003226361B2 (en) * 2002-11-06 2009-01-22 Celgene Corporation Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of myeloproliferative diseases
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
EP2407169A1 (en) * 2004-04-22 2012-01-18 Celator Pharmaceuticals, Inc. Combination formulations of anthracycline agents and cytidine analogs
SE0402025D0 (sv) * 2004-08-13 2004-08-13 Active Biotech Ab Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent
EP1976485A4 (en) 2005-12-22 2011-10-26 Celator Pharmaceuticals Inc LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF

Also Published As

Publication number Publication date
NO2022027I1 (no) 2022-06-30
DK2120568T3 (en) 2017-12-11
FR22C1034I1 (fr) 2022-09-09
HUE058334T2 (hu) 2022-07-28
EP4046640A1 (en) 2022-08-24
EP2120568A2 (en) 2009-11-25
PL3300601T3 (pl) 2022-05-02
DK3300601T3 (da) 2022-03-21
NL301185I2 (nl) 2022-07-21
US8092828B2 (en) 2012-01-10
PT3300601T (pt) 2022-04-21
PT2120568T (pt) 2017-12-04
FR22C1034I2 (fr) 2023-06-30
CY1119631T1 (el) 2018-04-04
NO2120568T3 (enExample) 2018-04-14
ES2909903T3 (es) 2022-05-10
AU2008216083B2 (en) 2014-02-06
CA2678332C (en) 2015-06-02
KR20150038752A (ko) 2015-04-08
CN105998046A (zh) 2016-10-12
AU2008216083A1 (en) 2008-08-21
EP2120568B1 (en) 2017-11-15
KR20100014441A (ko) 2010-02-10
EP3300601B1 (en) 2022-01-12
HRP20220428T3 (hr) 2022-05-27
WO2008101214A3 (en) 2008-11-20
HK1253378A1 (en) 2019-06-14
PL2120568T3 (pl) 2018-03-30
US20100303895A1 (en) 2010-12-02
JP5314600B2 (ja) 2013-10-16
JP2010519224A (ja) 2010-06-03
AU2008216083A2 (en) 2009-09-24
SI3300601T1 (sl) 2022-05-31
HUS2200032I1 (hu) 2022-07-28
LUC00271I2 (enExample) 2025-04-25
EP2120568A4 (en) 2010-04-21
CA2678332A1 (en) 2008-08-21
US20080199515A1 (en) 2008-08-21
WO2008101214A2 (en) 2008-08-21
EP3300601A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
ES2650167T3 (es) Relaciones farmacológicas fijas para el tratamiento de cánceres hematopoyéticos y trastornos proliferativos
Taniguchi et al. Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy
ES2426784T3 (es) Tratamiento de cánceres de la sangre usando compuestos glicomiméticos seleccionados
CN115645388B (zh) 氨基酸组合物及其用途
RU2011127456A (ru) Sparc-связывающие пептиды и их применение
WO2006047744A2 (en) Compositions of lactoferrin related peptides and uses thereof
AR081948A2 (es) USO DE b DEFENSINAS DE MAMIFEROS PARA LA MANUFACTURA DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS DEL INTESTINO
RU2011129672A (ru) Фармацевтический препарат
RU2008146734A (ru) Новый подход к лечению компартмент-синдрома
Lenertz et al. Control of bone development by P2X and P2Y receptors expressed in mesenchymal and hematopoietic cells.
KR101865420B1 (ko) 벡터적 이온 채널의 조절을 위한 유기화합물
WO2007022537A2 (en) Use of lactoferrin as a chemokine and a chemotactic modulator
Han et al. Inhibited glutamate release by granulocyte-colony stimulating factor after experimental stroke
CN113577070A (zh) 一种治疗急性髓系白血病的联合用药物组合物及其应用
JP2002302447A (ja) 局所投与用癌治療剤
KR102292069B1 (ko) 돌돔 인지질분해효소 유래의 항균 펩타이드를 유효성분으로 함유하는 암 치료용 약학적 조성물
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
CN101642465A (zh) 广东海风藤多糖在制备预防和/或治疗老年性痴呆症药物中的应用
Liu et al. Role of Citicoline in promoting the repair of acute peripheral nerve injury in rat models
AU2002357115B2 (en) Treatment of glioblastoma with thymosin-alpha 1
Oršolić et al. Direct antitumor activity of honey bee venom in vivo and in vitro
Liu et al. Low-Intensity Pulsed Ultrasound Ameliorates Neuropathic Pain Induced by Partial Sciatic Nerve Ligation Via Regulating Macrophage Polarization
Shaienko USE OF NANODISPERSIVE DERMATOTROPIC GEL IN THE COMPREHENSIVE TREATMENT OF TROPHIC LESIONS OF THE LOWER LIMBS IN PATIENTS WITH DIABETES MELLITUS
Wlodarek Characterizing the Mechanism of Young Bone Marrow-Derived Microglia-Like Cells on Restoring Cognitive Function in the Aged Brain and After Ischemic Injury
KR100674604B1 (ko) 싸이클릭다이펩타이드를 주성분으로 하는 방사선 보호제